Publication Topic

Xue Y, Wang L, Huo R, Chen M, Melo B, Dingley K, et al. 2024. 1β-Hydroxydeoxycholic acid as an endogenous biomarker in human plasma for assessment of CYP3A clinical drug-drug interaction potential. Drug Metab Dispos 52(9):966–974; doi: 10.1124/dmd.124.001680. PMID: 38991779.

Mihalchik AL, Choksi NY, Roe AL, Wisser M, Whitaker K, Seibert D, Deore M, Pavlick L, Wikoff DS. 2024. Safety evaluation of 8 drug degradants present in over-the-counter cough and cold medications. Regul Toxicol Pharmacol 149(May):105621; doi: 10.1016/j.yrtph.2024.105621. PMID: 38608922.

Burnett J, Sychterz C, Zhu D, Shakeel F, Dingley K, Chen W, et al. Prospective application of physiologically based pharmacokinetic (PBPK) modeling to inform the design of a clinical drug-drug interaction (DDI) study: Case study of mezigdomide. Poster presented at American Society of Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting, Colorado Springs, CO, March 2024.

Knotts T, Diokno R, Husfeld C, Weinberger D, Mease K, Wollowitz S, Kramer S, Donovan J. Vocacapsaicin (formerly CA-008): A water-soluble prodrug for rapid release of capsaicin for the treatment of postsurgical pain. Presentation to American Association of Pharmaceutical Scientists, AAPS PHARMSCI 360, Boston, MA, October 2022.

Robison TW. How many doses of an Ames-positive/mutagenic (DNA reactive) drug can be safely administered to healthy subjects? Genetic Toxicology Association, 2021.

Dake MD, Fanelli F, Lottes AE, O’Leary EE, Reichert H, Jiang X, Fu W, Iida O, et al. 2021. Prediction model for freedom from TLR from a multi-study analysis of long-term results with the Zilver PTX drug-eluting peripheral stent. Cardiovasc Intervent Radiol 44(2):196-206; doi: 10.1007/s00270-020-02648-6. PMID: 33025243.

Elbeddini A, Tayefehchamani Y, Davey M, Gallinger J, Hooda N, Aly A, Erickson D, Lee S. 2021. Fournier’s gangrene with dapagliflozin in a rural hospital: A case report. BMJ Case Rep 14(2):e237784; doi: 10.1136/bcr-2020-237784. PMID: 33526523.

Elbeddini A, Hooda N, Gazarin M, Webster P, McMillan J. 2020. Irinotecan-associated dysarthria in patients with pancreatic cancer: A single site experience. Am J Case Rep 21:e924058; doi: 10.12659/AJCR.924058. PMID: 32594093.

Belair DG, Waller L, Gustin J, Collins N, Kolaja K. Thalidomide inhibits human iPSC mesendoderm differentiation by modulating cereblon-dependent degradation of SALL4. Abstract #3296, Society of Toxicology 58th Annual Meeting, Baltimore, MD, March 2019.

Beebe-Dimmer JL, Ruterbusch JJ, Bylsma LC, Gillezeau C, Fryzek J, Schultz NM, Flanders SC, Barlev A, et al. 2018. Patterns of bicalutamide use in prostate cancer treatment: A U.S. real-world analysis using the SEER-Medicare database. Adv Ther 35(9):1438-1451; doi: 10.1007/s12325-018-0738-5. PMID: 29946798.

Belair DG, Collins N, Kolaja K. An in vitro assay of limb bud formation to study thalidomide-induced teratogenicity. Abstract and poster presented at the Gordon Research Conference — Signal Transduction by Engineered Extracellular Matrices, Proctor Academy, Andover, NH, 2018.

Soff GA, Ray-Coquard I, Marfil Rivera LJ, Fryzek J, Mullins M, Bylsma LC, Park JK. Literature review of thrombopoietin receptor agonists (TPO-RA) for chemotherapy-induced thrombocytopenia (CIT). Presented at the European Society for Medical Oncology 2017 Congress, Madrid, Spain, September 2017.

Miller B. Analysis of the fetal immunological response to diacetylmorphine and methadone using avian models. Presentation at Eastern Colleges Science Conference, Niagara University, Niagara, NY, April 2016. (Received Excellence Awards for Manuscript of Research and Oral Presentation of Research)

Miller B. Study of the immunological response to diacetylmorphine and methadone using avian model. Presentation at American Association for the Advancement of Science, Washington, DC, February 2016.

Sane RS, Steinmann GG, Huang Q, Li Y, Podila L, Mease K, Olson S, Taub ME, et al. 2014. Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in HCV patients. J Pharmacol Exp Ther 351(2):403–412; doi: 10.1124/jpet.114.218081. PMID: 25204339.

Moyes CR, Berger R, Goble SD, Harper B, Shen DM, Wang L, … Dingley KH, et al. 2014. Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective β3 adrenergic receptor agonists for the treatment of overactive bladder. J Med Chem 57(4):1437–1453; doi: 10.1021/jm4017224. PMID: 24437735.

Robison TW. Regulatory review of XELJANZ® (Tofacitinib) from the nonclinical perspective. American College of Toxicology Annual Meeting, 2013.

Mease K, Sane RS, Podila L, Taub ME. 2012. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: A strategy to assess the interaction of a new chemical entity with P-gp, BCRP and MRP2. J Pharm Sci 101(5):1888–1897; doi: 10.1002/jps.23069. PMID: 22359351.

Taub ME, Mease K, Sane RS, Watson CA, Chen L, Ellens H, Hirakawa B, Reyner EL, et al. 2011. Digoxin is not a substrate for organic anion transporting polypeptide transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a substrate for a sodium dependent transporter expressed in HEK293 cells. Drug Metab Disp 39(11):2093–2102; doi: 10.1124/dmd.111.040816. PMID: 21849517.

Poulet FM, Penraat K, Collins N, Evans E, Thackaberry E, Manfra D, et al. 2010. Drug-induced hemolytic anemia and thrombocytopenia associated with alterations of cell membrane lipids and acanthocyte formation. Toxicol Pathol 38(6):907–922; doi: 10.1177/0192623310378865. PMID: 20805317.